Pharmaceuticals Germany

Germany Lung Cancer Therapeutics Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Germany Lung Cancer Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Germany · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.48 Bn Placeholder estimate
Estimate 2025 $1.60 Bn 4% of the global market
Projected 2034 $3.31 Bn 106.7% Adds $1.71 Bn over 9 forecast years
CAGR 2025–2034 8.4% Faster than 61% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Germany is 4.01% of the global market.
  • In Europe, the largest is Germany (this report) at $1.60 Bn.
  • Fastest growing: Russia at 10.2% a year.
  • Germany ranks 1st of 6 by size in Europe.

Market size projection

Germany

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.71 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Lung Cancer Therapeutics Market market size by year, Germany
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.48 Bn — —
2025 (base) $1.60 Bn +$124.0 Mn —
2026 (forecast) $1.73 Bn +$134.4 Mn +8.4%
2027 (forecast) $1.88 Bn +$145.7 Mn +17.5%
2028 (forecast) $2.04 Bn +$158.0 Mn +27.4%
2029 (forecast) $2.21 Bn +$171.3 Mn +38.1%
2030 (forecast) $2.40 Bn +$185.6 Mn +49.7%
2031 (forecast) $2.60 Bn +$201.2 Mn +62.2%
2032 (forecast) $2.81 Bn +$218.1 Mn +75.9%
2033 (forecast) $3.05 Bn +$236.5 Mn +90.6%
2034 (forecast) $3.31 Bn +$256.3 Mn +106.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Germany Lung Cancer Therapeutics Market Analysis at a glance
Market size, 2025$1.60 Bn placeholder estimate
Forecast, 2034$3.31 Bn placeholder estimate
Growth (CAGR), 2025–20348.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, type and end user (see all)
Key playersMerck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and 1 more (see all)
Regulator in GermanyBfArMSource: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
Active clinical trials297 in GermanySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Germany Lung Cancer Therapeutics Market Analysis Executive Summary

Lung cancer therapeutics include targeted drugs, immunotherapy, chemotherapy and antibody-drug conjugates for small-cell and non-small cell lung cancer.

Key segments of the lung Cancer Therapeutics market include drug class (Targeted Therapy, Immunotherapy and Chemotherapy) and type (Non-Small Cell Lung Cancer and Small Cell Lung Cancer).

Bar chart: Germany Lung Cancer Therapeutics market size, 2024–2034, placeholder estimates. $1.48 Bn in 2024, $1.60 Bn in 2025 and $3.31 Bn in 2034, 8.4% CAGR.
Germany Lung Cancer Therapeutics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Germany Lung Cancer Therapeutics Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the lung Cancer Therapeutics market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the lung Cancer Therapeutics market, especially in low- and middle-income countries.

Competitive Landscape for Lung Cancer Therapeutics Market in Germany

The lung Cancer Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Lung Cancer Therapeutics Market in Germany

Lung Cancer Therapeutics in Germany: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut.⁠[1] Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines.⁠[2] ClinicalTrials.gov lists 297 studies on Lung Cancer Therapeutics that are recruiting, active or about to start in Germany.⁠[3]

[1] Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.

[2] Federal Joint Committee (G-BA). Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lung Cancer Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Germany.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Lung Cancer Therapeutics right now, from free public sources.

Clinical trials

297 active trials in Germany

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. AstraZeneca 79 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Merck & Co., Inc. 31 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sichuan Baili Pharmaceutical Co., Ltd. 22 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Bristol-Myers Squibb 19 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Johnson & Johnson 17 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Lung Cancer Therapeutics in context

Germany compared

  • Health spending per person: 6,849 US$ per person (2024). World: 1,317 US$ per person (2023). Highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.53 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 23.7% of people (2025). World: 10.4% of people (2025). 2nd highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Lung Cancer Therapeutics market in Germany?
Placeholder estimate: about $1.60 Bn in 2025, rising to about $3.31 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lung Cancer Therapeutics market in Germany growing?
Placeholder estimate: about 8.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lung Cancer Therapeutics market report cover?
The report splits the market by drug class (Targeted Therapy, Immunotherapy, Chemotherapy, Antibody-Drug Conjugates), type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lung Cancer Therapeutics market?
Key players include Merck & Co., Inc., AstraZeneca, Roche, Bristol-Myers Squibb, Amgen Inc. and Johnson & Johnson.
What is driving the Lung Cancer Therapeutics market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the lung Cancer Therapeutics market. Faster approvals and new combinations are improving survival.
Who regulates Lung Cancer Therapeutics in Germany?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by BfArM or, for vaccines and blood products, the Paul-Ehrlich-Institut. Source: Federal Institute for Drugs and Medical Devices (BfArM). Checked 14 Nov 2026.
How is healthcare paid for in Germany?
Most people have statutory health insurance; the Federal Joint Committee (G-BA) decides what it covers and rates the added benefit of new medicines. Source: Federal Joint Committee (G-BA). Checked 14 Nov 2026.
How many clinical trials on Lung Cancer Therapeutics are running in Germany?
297 studies are recruiting, active or about to start in Germany, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Germany. Retrieved 12 Nov 2026.
How much research is published on Lung Cancer Therapeutics?
PubMed lists 50 papers on Lung Cancer Therapeutics added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Germany

See all

Related on oncology and respiratory

See the topic